Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 3, 2009

Response Genetics to Support Roche’s Cancer Test Development

  • Roche Diagnostics will use Response Genetics’ PCR analysis platform to assess HER2 gene expression. The accurate measurement of HER2 gene expression can assist with treatment decisions for cancer patients.

    It has been shown that women with HER2-positive gene expression have a three times higher risk of recurrence, even if the cancer is caught in the early stages. HER2 gene amplification has been shown to correlate with improved clinical outcome in response to certain cancer drugs and its measurement by RT PCR was recently shown to correlate with analyses by fluorescence in situ hybridization and immunohistochemistry.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »